Atezolizumab before bladder or kidney-tract surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests atezolizumab (an immune therapy) given before surgery for certain bladder or upper urinary tract cancers. The goal is to shrink or control the cancer early and improve outcomes after curative surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign written consent
- You have urothelial cancer: bladder (T1 high grade to T4a) or upper urinary tract (renal pelvis/ureter) that is high-risk
- After prior bladder/urinary-tract procedures, there is still remaining cancer or it’s seen on scans/endoscopy
- Your scans show no spread to lymph nodes or other organs (N0 or M0) within 4 weeks
- A doctor plans curative surgery (bladder tumor resection leading to/then radical surgery, or kidney/ureter surgery such as nephroureterectomy/distal ureter resection)
- You can’t take or don’t plan to take neoadjuvant cisplatin chemotherapy, and you are well enough (ECOG 0–1) for study treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
This trial tests whether giving radiation therapy before surgery can help people with high-risk upper tract urothelial cancer (UTUC). The goal is to improve treatment outcomes for patients who are planning to have their cancer removed.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests whether giving chemotherapy before surgery can help people with high-risk upper tract urothelial cancer (a cancer in the kidney or ureter). The goal is to see if it improves outcomes for those who are healthy enough to receive cisplatin-based chemotherapy and undergo surgery.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) given before surgery can help patients with muscle-invasive bladder cancer or upper-tract urothelial cancer. The goal is to shrink tumors and improve outcomes before surgery removes the cancer.
Hear when a new Urogenital Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.